Keystone Resort Floorplan

Registered Attendees


Registered attendees (and speakers, organizers, etc.) will have access to the following items from their Account page:

  • Abstracts from speakers and poster sessions, including the joint meeting abstracts, available 30 days prior to the meeting (You can edit your own abstract from My Account page as well)

    NOTE: Abstract authors/submitters may choose to not have their abstract available online and in the secure mobile app until a week before the meeting.

  • Full participant list, including joint meeting participants
  • Printable Invoices and Invitation Letters
  • Scholarship Information
  • Lodging Information

Login to My Account page

This meeting took place in 2019



For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.

Innate and Non-Classical Immune Cells in Cancer Immunotherapy (C5)


Organizer(s) Nicholas D. Huntington, Eric Vivier, Caroline Robert and Lewis L. Lanier
March 24—28, 2019
Keystone Resort • Keystone, Colorado USA
Discounted Abstract Deadline: Dec 4, 2018
Abstract Deadline: Dec 13, 2018
Scholarship Deadline: Dec 4, 2018
Discounted Registration Deadline: Jan 23, 2019

Sponsored by BioLegend, Inc.

Summary of Meeting:
Immunotherapy has revolutionized the treatment of many cancer types over the past five years. T cell checkpoint inhibitors have led the way and are the focus of most immunotherapy trials. However innate and non-classical T cells contribute extensively to the tumor infiltrate and significantly impact on the tumor immune response in both the tumor microenvironment and in circulation. This symposium aims to bring together academic and industry opinion leaders in the fields of innate immune cells, natural killer cells, tumor microenvironment, tumor immune suppression, novel immunotherapeutic strategies and clinical cancer immunotherapy to define the next wave of immunotherapy breakthroughs that reach beyond the current T cell checkpoints. The conference offers a unique opportunity for an audience of diverse immunology and cancer research backgrounds to come together and share cutting edge insights into cancer immunology and rational approaches for therapeutic intervention that could be used as be standalone therapy or in combination with T cell checkpoint therapies. A key aim is to bring together experts with complementary interest in cancer immunotherapy that would not normally be drawn to common symposia and foster new dynamic collaborations to advance our understanding of tumor immunity.

View Scholarships/Awards
No registration fees are used to fund entertainment or alcohol at this conference

Conference Program    Print  |   View meeting in 24 hr (international) time


The meeting will begin on Sunday, March 24 with registration from 16:00 to 20:00 and a welcome mixer from 18:00 to 20:00. Conference events conclude on Thursday, March 28 with a closing plenary session from 17:00 to 19:00, followed by a social hour and entertainment. We recommend return travel on Friday, March 29 in order to fully experience the meeting.

SUNDAY, MARCH 24

4:00—8:00 PM
Arrival and Registration

Longs Peak Foyer
6:00—8:00 PM
Welcome Mixer
No registration fees are used to fund alcohol served at this function.

Longs Peak Foyer

MONDAY, MARCH 25

7:00—8:00 AM
Breakfast

Longs/Quandary Peaks
8:00—9:00 AM
Welcome and Keynote Address
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Nicholas D. Huntington, Walter and Eliza Hall Institute, WEHI, Australia

Ronald Levy, Stanford University, USA
In situ Therapeutic Vaccination with TLR Agonists

9:00—11:30 AM
Clinical and Industry Advances in Cancer Immunotherapy
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Caroline Robert, Institute Gustave Roussy, France
Advances in Melanoma Immunotherapy

Coffee Break

Robert J. Johnston, Bristol-Myers Squibb, USA
VISTA Is a pH-Selective PSGL-1 Ligand

Stephan Vagner, Institut Curie, France
Translational Control of Immune Checkpoint and Consequences for Cancer Immunotherapy

Michael Donio, Arch Oncology, USA
Short Talk: Innate Checkpoint Inhibitor, AO-176, A Next Generation CD47 Antibody with Novel Anti-Cancer Properties

Michael Wichroski, Bristol-Myers Squibb, USA
Short Talk: Preclinical Characterization of BMS-986299, a First-In-Class NLRP3 Innate Agonist with Potent Antitumor Activity, Alone and in Combination with Checkpoint Blockade

11:30 AM—5:00 PM
On Own for Lunch

11:30 AM—1:00 PM
Poster Setup

Longs/Quandary Peaks
1:00—10:00 PM
Poster Viewing

Longs/Quandary Peaks
3:00—4:30 PM
Workshop 1: Recent Advances in Drugging the Innate Immune Response

Grays Peak
* Robert J. Johnston, Bristol-Myers Squibb, USA

Amit Kumar, Johns Hopkins University, USA
Protein Engineering of s-DAB389-IL2 for Cancer Immunotherapy and Reduced Vascular Leak Syndrome

Elizabeth Sturgill, Providence Cancer Institute, USA
Galectin-3 Inhibition with GR-MD-02 Synergizes with T Cell-Targeting Immunotherapy, Leading to Reduced Immune Suppression and Improved Overall Survival

Monia Draghi, Compass Therapeutics, USA
Preclinical Characterization of NKp30xBCMA, a Novel Class of NK-Cell Engagers

Brian J. Francica, Aduro Biotech, USA
Magnitude of Therapeutic STING Activation Critically Impacts CD8+ T Cell-Mediated Anti-Tumor Immunity

Carina Hage, Roche Diagnostics GmbH, Germany
Sorafenib Initiates Macrophage-Natural Killer Cell Crosstalk by Macrophage Pyroptosis

Manuela Zonca, PsiOxus Therapeutics, UK
NG-641: A Tumor Stroma Targeting Transgene-Bearing Oncolytic Virus

4:30—5:00 PM
Coffee Available

Longs Peak Foyer
5:00—7:15 PM
Myeloid Cells
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Stefani Spranger, Massachusetts Institute of Technology, USA
Cross-Presenting Dendritic Cells within the Tumor Microenvironment

Dmitry I. Gabrilovich, Wistar Institute, USA
Myeloid-Derived Suppressor Cells in Cancer: Targeting Opportunities

Weiping Zou, University of Michigan, USA
Myeloid Cells in Cancer Immunity and Cancer Stemness

Matthias Ernst, Olivia Newton-John Cancer Research Institute, Australia
Short Talk: Targeting the Myeloid-Cell Specific Kinase HCK Improves Anti-Tumor Immunity

Katherine Brempelis, Seattle Children's Research Institute, USA
Short Talk: Programming Macrophages to Alter the Solid Tumor Microenvironment

Anje Cauwels, VIB and Ghent University, Belgium
Short Talk: Specific Targeting of Type I Interferon to the Tumor Microenvironment or to Dendritic Cells as a Novel, Generic, Safe Cancer Immunotherapy

7:15—8:15 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Longs/Quandary Peaks
7:30—10:00 PM
Poster Session 1

Longs/Quandary Peaks

TUESDAY, MARCH 26

7:00—8:00 AM
Breakfast

Longs/Quandary Peaks
8:00—11:00 AM
ADCC and Phagocytosis
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Irving L. Weissman, Stanford University, USA
CD47 in Tumor Immunity

Sergio A. Quezada, University College London, UK
Impact of Fc/FcR Interaction on the Activity of Immune Modulatory Antibodies

Coffee Break

Mark S. Cragg, University of Southampton, UK
Tumour:Myeloid Interactions Mediating Antibody Immunotherapy

André Veillette, Institut de Recherches Cliniques de Montreal, Canada
Novel Roles of SLAM Family Receptors in Innate and Innate-Like Immune Cells

Nicholas Wilson, Gilead Biosciences, Inc., USA
Short Talk: Selective FcγR Co-Engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens

Darienne R. Myers, Revolution Medicines, USA
Short Talk: Shp1 Loss Drives Robust Anti-Tumor Immunity and Enhances Macrophage Effector Function

11:00 AM—5:00 PM
On Own for Lunch

11:00 AM—1:00 PM
Poster Setup

Longs/Quandary Peaks
1:00—10:00 PM
Poster Viewing

Longs/Quandary Peaks
4:30—5:00 PM
Coffee Available

Longs Peak Foyer
5:00—7:00 PM
Tumor Microenvironment
Meeting has ended...abstracts no longer viewable online.

Grays Peak
Marcus Ruscetti, Memorial Sloan Kettering Cancer Center, USA
NK Cell-Mediated Cytotoxicity Contributes to Tumor Control by a Cytostatic Drug Combination

* Ursula Grohmann, University of Perugia, Italy
An Intracellular Spatial Dynamics Dictates the Catalytic Versus Signaling Function of IDO1 in Dendritic Cells

Eric D. Frontera, Michigan State University, USA
Short Talk: IgA Fc-Folate Conjugate Activates and Recruits Neutrophils to Directly Target Triple-Negative Breast Cancer Cells

Chelsea Lassiter, University of Minnesota, USA
Short Talk: Targeting STAT3 in Breast Cancer Models

Ying Jiang, University of Virginia, USA
Short Talk: Multicellular Immunological Microenvironment Drives Tumor Initiation and Progression in Medulloblastoma

7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Longs/Quandary Peaks
7:30—10:00 PM
Poster Session 2

Longs/Quandary Peaks

WEDNESDAY, MARCH 27

7:00—8:00 AM
Breakfast

Longs/Quandary Peaks
8:00—11:00 AM
Innate Checkpoints
Meeting has ended...abstracts no longer viewable online.

Grays Peak
Carla V. Rothlin, Yale University, USA
Innate Immune Checkpoints in Cancer

Nicholas D. Huntington, Walter and Eliza Hall Institute, WEHI, Australia
Natural Killer Cell Response to Cancer

Coffee Break

Alberto Mantovani, Humanitas University, Italy
New Vistas on Tumor-Associated Macrophages and Interaction with NK cells

* Lewis L. Lanier, University of California, San Francisco, USA
NK Cell Memory to Cancer

Dan Fu Ruan, Icahn School of Medicine at Mount Sinai, USA
Short Talk: HLA-E Expression as a Major Determinant of Antitumor Function

Angela L. Tata, Brown University, USA
Short Talk: KLRG1 as a Novel Target for Immune Checkpoint Blockade

11:00 AM—5:00 PM
On Own for Lunch

11:00 AM—1:00 PM
Poster Setup

Longs/Quandary Peaks
1:00—10:00 PM
Poster Viewing

Longs/Quandary Peaks
4:30—5:00 PM
Coffee Available

Longs Peak Foyer
5:00—7:15 PM
Immune Evasion and Metastasis
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Caroline Robert, Institute Gustave Roussy, France

Kai W. Wucherpfennig, Dana-Farber Cancer Institute, USA
Targeting Immune Evasion from the MICA-NKG2D Pathway

Ilaria Malanchi, Francis Crick Institute, UK
Neutrophils in the Metastatic Niche

Sohail F. Tavazoie, Rockefeller University, USA
Metastatic Progression as a Model for Understanding Anti-Tumor Immunity

Sumera Rizvi, Mayo Clinic, USA
Short Talk: PD-L1+ Protumor Macrophages Facilitate Tumor Progression in Murine Cholangiocarcinoma

Debolina Ganguly, University of Texas Southwestern Medical Center, USA
Short Talk: Pleiotrophin and Midkine Promote Metastasis in Pre-Clinical Models of Breast Cancer

Hin Ching Lo, Baylor College of Medicine, USA
Short Talk: Circulating Tumor Cell Clusters Exhibit Enhanced Immune Evasion from Natural Killer Cells

7:15—8:15 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Longs/Quandary Peaks
7:30—10:00 PM
Poster Session 3

Longs/Quandary Peaks

THURSDAY, MARCH 28

7:00—8:00 AM
Breakfast

Longs/Quandary Peaks
8:00—11:00 AM
NK Cells and ILCs
Meeting has ended...abstracts no longer viewable online.

Grays Peak
* Eric Vivier, Centre d'Immunologie de Marseille-Luminy, Innate Pharma, France
Targeting NK Cells in Cancer

Xiaokui Zhang, Celularity Inc., USA
Adoptive NK Cell Therapies

Coffee Break

David H. Raulet, University of California, Berkeley, USA
Activation and Inhibition of NK Cells in the Tumor Microenvironment, and Applications to Therapy

Adelheid Cerwenka, University of Heidelberg, Germany
Unleashing Potent NK Cell Anti-Tumor Activity in Solid Tumors

Karl-Johan Malmberg, University of Oslo, Norway
Short Talk: Subset Plasticity and Functional Reprogramming during Natural Killer Cell Homeostasis

Robin S. Lindsay, University of Virginia, USA
Short Talk: NK Cells Increase T Cell Infiltration and Antigen Presenting Cell Maturation within Melanoma Tumors

11:00 AM—5:00 PM
On Own for Lunch

3:00—4:30 PM
Workshop 2: Cellular Therapies & Biomarkers

Grays Peak
* Nicholas D. Huntington, Walter and Eliza Hall Institute, WEHI, Australia

Chao Guo, Nkarta Therapeutics, USA
Short Talk: NK Cells Engineered to Express a Bispecific CD123/NKG2D Chimeric Antigen Receptor (CAR) and IL-15 As Off-the-Shelf Therapy for Acute Myeloid Leukemia

Xiao-Hua Li, University of California, San Diego, USA
Short Talk: Switchable Chimeric Antigen Receptor-Engineered iPSC-Derived Natural Killer Cells

Michael Klichinsky, Carisma Therapeutics, USA
Human Chimeric Antigen Receptor (CAR) Macrophages for Cancer Immunotherapy

Huang Zhu, University of California, San Diego, USA
Deletion of CISH in Human Stem Cell Derived Natural Killer Cells Promotes in vivo Persistence and Enhances Anti-Tumor Activity

Yago Pico de Coaña, Karolinska Institutet, Sweden
Monitoring Advanced Melanoma Patients after Checkpoint Blockade: NK Cells and MDSCs as Predictive Biomarkers

Richard P. Tobin, University of Colorado Anschutz Medical Campus, USA
Mucosal-Associated Invariant T Cells as a Novel Marker of Response to Anti-PD1 Therapy in Melanoma Patients

4:30—5:00 PM
Coffee Available

Longs Peak Foyer
5:00—6:45 PM
Emerging Techniques in Immunotherapy
Meeting has ended...abstracts no longer viewable online.

Grays Peak
Darrell J. Irvine, Massachusetts Institute of Technology, USA
Combination Immunotherapies Acting through Innate Immunity

* Thomas Gebhardt, Doherty Institute for Infection and Immunity, Australia
Imaging Melanoma Immune Homeostasis in the Skin

Bjorn Onfelt, KTH - Royal Institute of Technology, Sweden
Short Talk: Microchip Platform for Imaging-Based Efficacy Testing of Cells and Reagents for Immunotherapy

Davide Bernareggi, University of California, San Diego, USA
Short Talk: Use of CRISPR/Cas9 Screening System to Identify Genes that Regulate NK Cell-Mediated Killing of Glioblastoma and Meningioma

Adam Jelinski, Weizmann Institute, Israel
Short Talk: Single-Cell Analysis Illustrates Discrete Cellular Dynamics Generated Between A Pure Checkpoint Blocking Antibody, aCTLA4 mIgG1, and a Dual-Activity aCTLA4 mIgGa2 with Additional FcgR Engaging Activity

6:45—7:00 PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Meeting has ended...abstracts no longer viewable online.

Grays Peak
7:00—8:00 PM
Social Hour with Lite Bites
No registration fees are used to fund alcohol served at this function.

Longs/Quandary Peaks
8:00—11:00 PM
Entertainment
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Longs/Quandary Peaks

FRIDAY, MARCH 29

 
Departure


*Session Chair †Invited, not yet responded.



We gratefully acknowledge support for this conference from:


Directors' Fund


These generous unrestricted gifts allow our Directors to schedule meetings in a wide variety of important areas, many of which are in the early stages of research.

Click here to view all of the donors who support the Directors' Fund.



Keystone Symposia thanks our Sponsor for generously supporting this meeting:

BioLegend, Inc.

We gratefully acknowledge additional support from these exhibitors at this conference:

American Association for Cancer Research (AACR)
Please stop by to meet these exhibitors during the conference.


We gratefully acknowledge the generous grant for this conference provided by:


National Institutes of Health

Grant No. 1R13CA236119-01

Funding for this conference was made possible (in part) by 1R13CA236119-01 from the National Institutes of Health. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention by trade names, commercial practices, or organizations imply endorsement by the U.S. Government.


We gratefully acknowledge additional support for this conference from:

AdipoGen Life Sciences Servier
Innate Pharma oNKo-innate Pty Ltd

We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:



Bristol-Myers Squibb Company


Celularity Inc.


We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:


Click here to view more of these organizations


Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:


Click here to view more of these organizations


If your organization is interested in joining these entities in support of Keystone Symposia, please contact: Sarah Lavicka, Director of Development, Email: sarahl@keystonesymposia.org,
Phone:+1 970-262-2690

Click here for more information on Industry Support and Recognition Opportunities.

If you are interested in becoming an advertising/marketing in-kind partner, please contact:
Nick Dua, Senior Director, Communications, Email: nickd@keystonesymposia.org,
Phone:+1 970-262-1179